TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30658705

Group type: EXPERIMENTAL
Intervention: Active tDCS (0.048 mA/cm2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tDCS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 40
Study: 29429593

Group type: EXPERIMENTAL
Intervention: BDP/FF/G (beclometasone dipropionate, formoterol fumarate, and glycopyrronium) 87 μg/5 μg/9 μg, two inhalations per day
Number of subjects: 1532

Group type: COMPARATOR
Intervention: IND/GLY (indacaterol plus glycopyrronium) 85 μg/43 μg, one inhalation per day
Number of subjects: 1532
Study: 27614902

Group type: EXPERIMENTAL
Intervention: State EITC supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: State EITC supplements for a family of three
Number of subjects: 0
Study: 23835773

Group type: EXPERIMENTAL
Intervention: Yoga Respiratory Training (YRT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Inspiratory Threshold Training (ITT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control
Number of subjects: 81
Study: 22894937

Group type: EXPERIMENTAL
Intervention: Experimental instruction followed by practice in speeding responses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimental instruction alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Process-dissociation analysis
Number of subjects: 0
Study: 20205966

Group type: EXPERIMENTAL
Intervention: Minimally glycosylated GMP (3.5% NeuNAc, 1.5% Gal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glycosylated GMP (12.0% NeuNAc, 4.2% Gal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GMP-depleted whey protein concentrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 20
Study: 18602526

Group type: EXPERIMENTAL
Intervention: Fosinopril treatment for 3 months
Number of subjects: 621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study: 15809548

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilator (albuterol/ipratropium bromide solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study: 11823666

Group type: EXPERIMENTAL
Intervention: Postoperative hyperthermia (maximum temperature within the first 24 hours ranging from 37.2 degrees C to 39.3 degrees C)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Area under the curve for temperatures >37 degrees C
Number of subjects: 300
Study: 10965009

Group type: EXPERIMENTAL
Intervention: Bolus intrathecal injections of 50 microg of baclofen
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bolus intrathecal injections of 75 microg of baclofen
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Continuous intrathecal administration of baclofen via subcutaneous pump
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8791041

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg intravenous)
Number of subjects: 10
Study: 1611810

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam intravenously in 15 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg alpha-hydroxymidazolam intravenously in 15 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam orally
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6231156

Group type: EXPERIMENTAL
Intervention: Intravenous saralasin (0.5, 1 and 5 micrograms min‐1 kg‐1) in tetraplegic patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous saralasin (5 micrograms kg‐1 min‐1) in tetraplegic patients after alpha‐adrenoceptor blockade with thymoxamine (1 mg kg‐1 h‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous saralasin in both groups (tetraplegic patients and normal subjects)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Basal plasma renin activity in both groups
Number of subjects: 15
Study: 29623135

Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen Therapy (HFO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mask Oxygen Therapy
Number of subjects: 0
Study: 27015606

Group type: EXPERIMENTAL
Intervention: Immediate triple therapy (IT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate etanercept (IE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Step-up triple therapy (ST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Step-up etanercept (SE)
Number of subjects: 0
Study: 24506739

Group type: EXPERIMENTAL
Intervention: Phaco‐NPDS
Number of subjects: 52

Group type: COMPARATOR
Intervention: NPDS
Number of subjects: 52
Study: 23610856

Group type: EXPERIMENTAL
Intervention: Indirect videolaryngoscopy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Classic direct laryngoscopy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Indirect videolaryngoscopy with beta blockade
Number of subjects: 80
Study: 20670756

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 11479

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 11479
Study: 18586124

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (supervised, group program, 6 exercises using weight machines, performed twice a week for 10 weeks, 2-3 sets of 10-12 repetitions until fatigue)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 20
Study: 16204706

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET
Number of subjects: 81

Group type: COMPARATOR
Intervention: CT
Number of subjects: 81
Study: 12006902

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11994246

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 301
Study: 9661603

Group type: EXPERIMENTAL
Intervention: pamidronate (APD) 30 mg i.v. every 3 months for 2 yr
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo (placebo/T4)
Number of subjects: 55
Study: 7663782

Group type: EXPERIMENTAL
Intervention: Survanta (n = 6)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Alveofact (n = 8)
Number of subjects: 23
Study: 2699997

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 grams added to dialysis bath for three months) during acetate hemodialysis
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 grams added to dialysis bath for three months) during bicarbonate hemodialysis
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo during acetate hemodialysis
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo during bicarbonate hemodialysis
Number of subjects: 9
Study: 832179

Group type: EXPERIMENTAL
Intervention: Intramuscular atropine as the only premedication
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous atropine at the time of induction of anaesthesia
Number of subjects: 120
Study: 6757458

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 0
Study: 31047905

Group type: EXPERIMENTAL
Intervention: Routine care plus urodynamics (UDS)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Routine, noninvasive tests (control)
Number of subjects: 820
Study: 29534997

Group type: EXPERIMENTAL
Intervention: 4 months of monthly degarelix (first dose 240 mg, subsequent doses 80 mg per month)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 months of monthly degarelix (first dose 240 mg, subsequent doses 80 mg per month)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 4 months of monthly degarelix
Number of subjects: 90

Group type: COMPARATOR
Intervention: 10 months of monthly degarelix
Number of subjects: 90
Study: 26728893

Group type: EXPERIMENTAL
Intervention: AZD2327 (3 mg BID)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 25109239

Group type: EXPERIMENTAL
Intervention: Zonisamide (200-500 mg/day)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Carbamazepine (400-1,200 mg/day)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 295

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 295
Study: 23197752

Group type: EXPERIMENTAL
Intervention: Suvorexant 10 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Suvorexant 80 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Suvorexant (all doses combined)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 20215976

Group type: EXPERIMENTAL
Intervention: Soy protein supplementation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 62
Study: 18557167

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (30 mg/kg over 10 minutes, then 10 mg/kg/hr throughout surgery)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15784063

Group type: EXPERIMENTAL
Intervention: Nefazodone (300 mg/day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 12641685

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg(‐1) + Midazolam 0.1 mg.kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg(‐1) + Midazolam 0.2 mg.kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg.kg(‐1) + Midazolam 0.2 mg.kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Halothane induction (comparison group)
Number of subjects: 80
Study: 10594542

Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone 80 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8701413

Group type: EXPERIMENTAL
Intervention: Recombinant thromboplastin (rTF, ISI = 0.82)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Rabbit thromboplastin (RT, ISI = 1.46)
Number of subjects: 67
Study: 2072220

Group type: EXPERIMENTAL
Intervention: Penicillin therapy only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Penicillin and prednisone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 6134298

Group type: EXPERIMENTAL
Intervention: Oral temazepam (20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30447052

Group type: EXPERIMENTAL
Intervention: Resistin concentration ≥ 11.4 ng/mL
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Higher resistin levels
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Resistin concentration above 11 ng/mL
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Univariate predictors
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Resistin
Number of subjects: 284
Study: 30308428

Group type: EXPERIMENTAL
Intervention: LEV-ER (extended-release levetiracetam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LEV-IR (immediate-release levetiracetam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LEV-ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: LEV-IR
Number of subjects: 0
Study: 27468543

Group type: EXPERIMENTAL
Intervention: A & As particle 15.2 g/day
Number of subjects: 158

Group type: COMPARATOR
Intervention: losartan 50 mg/day
Number of subjects: 158
Study: 24633208

Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine plus abacavir (cABC arm)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: nevirapine (cNVP arm)
Number of subjects: 600

Group type: COMPARATOR
Intervention: cNVP arm
Number of subjects: 600

Group type: COMPARATOR
Intervention: cABC arm
Number of subjects: 600
Study: 22926008

Group type: EXPERIMENTAL
Intervention: Computer-delivered tailored intervention
Number of subjects: 556

Group type: COMPARATOR
Intervention: Non-tailored print material (American Cancer Society brochure)
Number of subjects: 556
Study: 20003628

Group type: EXPERIMENTAL
Intervention: Speed of processing intervention
Number of subjects: 2802

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 2802

Group type: COMPARATOR
Intervention: Memory intervention
Number of subjects: 2802

Group type: COMPARATOR
Intervention: Reasoning intervention
Number of subjects: 2802
Study: 17914073

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 342

Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 342
Study: 16534240

Group type: EXPERIMENTAL
Intervention: 100 microg intravenously administered CRH
Number of subjects: 16

Group type: COMPARATOR
Intervention: 12 mg naloxone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12011663

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg three times a day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Lisinopril (10-20 mg once daily)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Valsartan (80-160 mg once daily)
Number of subjects: 128
Study: 10850318

Group type: EXPERIMENTAL
Intervention: 500 mg/m2 amifostine intravenously prior to HD-RIT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiological saline solution (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 200 mg/kg amifostine prior to HD-RIT in rabbits
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control rabbits (no amifostine)
Number of subjects: 50
Study: 8709384

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 with sodium bicarbonate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prostaglandin E1 without sodium bicarbonate
Number of subjects: 10
Study: 1936073

Group type: EXPERIMENTAL
Intervention: Rokitamycin 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rokitamycin 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rokitamycin 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rokitamycin 600 mg
Number of subjects: 12
Study: 6791673

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Trinitroglycerine
Number of subjects: 22
Study: 29525393

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3851

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Intervention (active vitamin D sterol dose increase)
Number of subjects: 3851
Study: 27508314

Group type: EXPERIMENTAL
Intervention: Comprehensive Reminder System (health belief education, calendar handbook, weekly automated SMS, four telephone follow-ups)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24886036

Group type: EXPERIMENTAL
Intervention: Lecithinized superoxide dismutase (40 or 80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lecithinized superoxide dismutase (80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22429451

Group type: EXPERIMENTAL
Intervention: Short-stretch bandaging (SSB)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Four-layer bandaging (4LB)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Usual care (moist wound healing dressing without compression)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Compression-treated groups (SSB and 4LB)
Number of subjects: 321
Study: 20563466

Group type: EXPERIMENTAL
Intervention: Morphine PCA alone (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Morphine PCA plus continuous infusion (Group B)
Number of subjects: 100
Study: 18520951

Group type: EXPERIMENTAL
Intervention: Fosinopril/hydrochlorothiazide combination (10/12.5 mg titrated up to 20/12.5 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Amlodipine (5 mg titrated up to 10 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Indapamide (2.5 mg)
Number of subjects: 28
Study: 15939732

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline 0.5 mg/kg/hour after an appropriate loading dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 80
Study: 12463729

Group type: EXPERIMENTAL
Intervention: Galantamine and risperidone administered together
Number of subjects: 16

Group type: COMPARATOR
Intervention: Galantamine and risperidone administered alone
Number of subjects: 16
Study: 10618647

Group type: EXPERIMENTAL
Intervention: Fenretinide (synthetic retinoid)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Conventional cytology
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: DNA flow cytometry
Number of subjects: 99
Study: 7851589

Group type: EXPERIMENTAL
Intervention: 16 mg oral 6-alpha-methylprednisolone for four evenings starting the evening of retrieval or the evening before thawing cryopreserved embryos, plus 250 mg oral tetracycline four times per day for 4 days.
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo administered in an identical fashion, plus 250 mg oral tetracycline four times per day for 4 days.
Number of subjects: 267
Study: 1658546

Group type: EXPERIMENTAL
Intervention: hCRH plus 0.3 U IV AVP
Number of subjects: 16

Group type: COMPARATOR
Intervention: hCRH alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: hCRH plus 3.0 U IM AVP
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: hCRH plus 5.0 U IM AVP
Number of subjects: 16
Study: 6127319

Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg body weight) + Cefotaxime (2 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefotaxime (2 g)
Number of subjects: 30
Study: 31169417

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) for 12 weeks, 36 sessions total.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sedentary control group (no specific intervention mentioned).
Number of subjects: 30
Study: 28623433

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 56

Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 56
Study: 25376729

Group type: EXPERIMENTAL
Intervention: SIE (sprint interval exercise; 4 all-out 30-s sprints)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CELOW (continuous exercise at 46% VO2peak)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CEHIGH (continuous exercise at 77% VO2peak)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON (non-exercise trial)
Number of subjects: 10
Study: 23351827

Group type: EXPERIMENTAL
Intervention: LABR‐312 (low-dose)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: LABR‐312 (high-dose)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: LABR‐312 (inflammatory patient group)
Number of subjects: 225
Study: 21081771

Group type: EXPERIMENTAL
Intervention: Anesthesiologists ordering tests
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Anesthesiologists
Number of subjects: 1000
Study: 19336860

Group type: EXPERIMENTAL
Intervention: Oil pulling with sesame oil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 20
Study: 16629914

Group type: EXPERIMENTAL
Intervention: Self‐Efficacy Goal Achievement nursing intervention
Number of subjects: 8
Study: 15152381

Group type: EXPERIMENTAL
Intervention: Preventive strategies including staff education, increasing safety during nursing interventions, research for risk indicators of self‐extubation, patient's comfort and sedation protocols, alternative methods to physical and pharmacological restraints.
Number of subjects: 0
Study: 11703951

Group type: EXPERIMENTAL
Intervention: Eptifibatide 135 microg/kg bolus followed by 0.75 microg/kg/min infusion
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Eptifibatide 180 microg/kg bolus followed by 2.0 microg/kg/min infusion
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Eptifibatide 250 microg/kg bolus followed by 3.0 microg/kg/min infusion
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 9141536

Group type: COMPARATOR
Intervention: [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg, administered nightly for 16 weeks after 4 weeks of placebo.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline) self-injected s.c. nightly for 4 weeks.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: [Nle27]GHRH-(1-29)-NH2
Number of subjects: 19
Study: 7867114

Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride, 0.03 mg.kg‐1 iv
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride, 0.1 mg.kg‐1 iv
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study: 2765348

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 15 mg plus clonidine 1 ml (150 micrograms)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% isobaric bupivacaine 15 mg plus isotonic saline 1 ml
Number of subjects: 30
Study: 49560

Group type: EXPERIMENTAL
Intervention: Self-administered nitrous oxide 50%/oxygen 50% ('Entonox' analgesic apparatus)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 81
Study: 31393430

Group type: EXPERIMENTAL
Intervention: Section of SLIL+LRL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Section of SLIL+DIC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Section of SLIL+STT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Section of SLIL+DIC+DIC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Division of SLIL
Number of subjects: 30
Study: 25578926

Group type: EXPERIMENTAL
Intervention: ¡Cocinar Para Su Salud! (Intervention group, n=34)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 70
Study: 23222003

Group type: EXPERIMENTAL
Intervention: Intracoronary nitroglycerin (250-μg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (5-mg)
Number of subjects: 60
Study: 21624218

Group type: EXPERIMENTAL
Intervention: Early intervention group (coronary angiography taken within 24 hours after grouping)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Delayed intervention group (coronary angiography taken after 36 hours after grouping)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Early intervention group
Number of subjects: 815

Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 815